careful - the record
TB-500 Legal Status, FDA 503A Category, and Compounding Access
The regulatory record, read with passport-photo composure: where the FDA placed it, what that means, and why access is genuinely under active review heading into 2026 — without a single decision stated as already made.
Where TB-500 legal status stands right now
The TB-500 legal status, read honestly, has two halves: a present-tense FDA fact and a forward-leaning question. Start with the momentum, then anchor it. Access to TB-500 through legal compounding is under active FDA review and may expand in 2026 — and that statement rests on something concrete and published, not on speculation.
The concrete fact: 'TB-500 (free base)' and 'TB-500 acetate' are individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as bulk drug substances 'being considered for inclusion on the 503A Bulks List' [17][19]. The same agenda also lists BPC-157, KPV, and MOTs-C [19]. That is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in current status.
The current status, stated present-tense: TB-500 — which FDA lists as 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' — is a research peptide that FDA placed in 503A Category 2 (bulk substances that may present significant safety risks). That placement became effective with FDA's September 29, 2023 update to the list of nominated substances, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information [18]. As a Category 2 substance it is not within FDA's enforcement-discretion policy for 503A compounding, and it is not an FDA-approved drug [18].
What Category 2 actually means under 503A
Drug compounding in the U.S. is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight [20].
A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list. Substances not yet listed are evaluated by FDA through a public nomination process, with input from PCAC [20].
Under FDA's interim policy, nominated substances were sorted into categories. Category 1 substances were covered by FDA's enforcement-discretion policy while under evaluation. Category 2 substances are those FDA identified as raising significant safety risks; they are not afforded that discretion, and FDA stated it would consider taking action against a compounder using one [21]. TB-500 sits in Category 2. Separately, on January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories, while substances already in Category 2 are not afforded enforcement discretion even if nominations are updated [20]. Inclusion on a final bulks list is decided by FDA rulemaking informed by PCAC; being discussed by PCAC is a step in evaluation, not a final listing decision [19].
How legally compounded peptide access works
This is general information about the lawful pathway, described without naming any pharmacy, clinic, telehealth provider, or vendor — and without any dosing.
A legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber, in person or through a compliant telehealth encounter, who determines that a compounded preparation is clinically appropriate. If appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility [20].
Telehealth is one channel for the prescriber-evaluation step that begins this pathway — a route to a licensed-prescriber consultation and prescription, not a separate legal status. It does not expand which substances may be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription [20]. The decisive caveat for TB-500: a compounder may use a requested ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. An ingredient FDA has flagged for significant safety risks — a Category 2 substance — is not eligible for routine 503A compounding while that status stands [20]. That is the operative limit on access today, and it is exactly the question the July 2026 PCAC meeting is scheduled to take up.
None of this is medical or legal advice, and none of it is an offer to sell or supply any substance.
Legal and regulatory questions, answered directly
Is TB-500 legal?
TB-500 is not an FDA-approved drug and is not within FDA's enforcement-discretion policy for 503A compounding, because FDA placed 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' in Category 2 (significant safety risks), effective with its September 29, 2023 update [18]. It is sold by suppliers for research and veterinary use. It is also prohibited in sport by WADA and is a prescription medicine in some jurisdictions [22]. This is general information, not legal advice.
Can you get TB-500 from a compounding pharmacy?
A legally compounded preparation requires a licensed-prescriber evaluation and a valid, patient-specific prescription, dispensed by a 503A pharmacy or sourced from a 503B outsourcing facility [20]. But a compounder may use an ingredient only if it is eligible under the bulk-substance rules, and a Category 2 substance is not eligible for routine 503A compounding while that status stands — which is TB-500's current position [20][18].
What is the FDA 503A status of TB-500?
FDA placed TB-500 (listed as 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500') in 503A Category 2 — bulk substances that may present significant safety risks — effective with the September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information [18]. It is named on the July 23–24, 2026 PCAC agenda for evaluation, which is a scheduled discussion, not a decision [19].
Is TB-500 FDA approved?
No. TB-500 has no FDA-approved therapeutic indication and is not an FDA-approved drug [18]. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding; TB-500 is neither approved as a finished drug nor currently eligible for routine 503A compounding [20][18].
Is TB-500 banned by WADA and in competitive sports?
Yes. TB-500 and thymosin beta-4 fall under WADA's prohibited peptide, growth-factor, and tissue-repair categories, banned both in and out of competition [22]. It is detected by LC-MS anti-doping assays and has been encountered as a designer drug in racehorses, prompting equine and human detection methods [5].